Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Thireau

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Reply to H.J. Lee et alJohn R Mackey, Vincent Houé, Francois Thireau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
Final Survival Analysis of ROSE/TRIO-012John R Mackey, Nicole McCarthy, Karen A Gelmon, et al.
Breast Cancer Research and Treatment|January 23, 2025
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancerCatherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Breast Cancer Research and Treatment|March 19, 2026
Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancerCatherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Reply to H.J. Lee et alJohn R Mackey, Vincent Houé, Francois Thireau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
Final Survival Analysis of ROSE/TRIO-012John R Mackey, Nicole McCarthy, Karen A Gelmon, et al.
Breast Cancer Research and Treatment|January 23, 2025
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancerCatherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Breast Cancer Research and Treatment|March 19, 2026
Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancerCatherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Pageof 1